These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4616332)

  • 1. Influence of two different beta-adrenergic blocking agents on the increase in fibrinolytic activity and factor VIII activity during submaximum and maximum exercise.
    Korsan-Bengtsen K; Conradson TB
    Scand J Haematol; 1974; 13(5):377-84. PubMed ID: 4616332
    [No Abstract]   [Full Text] [Related]  

  • 2. Alterations of fibrinolysis and blood coagulation induced by exercise, and the role of beta-adrenergic-receptor stimulation.
    Cohen RJ; Epstein SE; Cohen LS; Dennis LH
    Lancet; 1968 Dec; 2(7581):1264-6. PubMed ID: 4177470
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect propranolol, alprenolol and practolol on the vibrinolytic and factor VIII responses to adrenaline and salbutamol in man.
    Gader AM; Da Costa J; Cash JD
    Thromb Res; 1974 Jan; 4(1):25-33. PubMed ID: 4829668
    [No Abstract]   [Full Text] [Related]  

  • 4. Alprenolol alone and in conjunction with pentanitrol in angina pectoris. A double-blind study with exercise tests.
    Hansen PF; Rasmussen PA; Nyberg G
    Acta Med Scand; 1973 May; 193(5):419-24. PubMed ID: 4197873
    [No Abstract]   [Full Text] [Related]  

  • 5. Hemodynamic effects of adrenergic beta-receptor blocking agents.
    Sannerstedt R
    Adv Clin Pharmacol; 1976; 11():70-8. PubMed ID: 25571
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of two adrenergic beta-receptor blocking agents, alprenolol and propranolol, in treatment of angina pectoris.
    Heterington DJ; Comerford MB; Nyberg G; Besterman EM
    Br Heart J; 1973 Mar; 35(3):320-33. PubMed ID: 4632566
    [No Abstract]   [Full Text] [Related]  

  • 7. The inability of propranolol and aspirin to inhibit the response of fibrinolytic activity and factor VIII-antigen to infusion of DDAVP.
    Brommer EJ; Derkx FH; Barrett-Bergshoeff MM; Schalekamp MA
    Thromb Haemost; 1984 Feb; 51(1):42-4. PubMed ID: 6426080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alprenolol and propranolol in the treatment of hypertension: a comparative study.
    Somer T; Luomanmäki K; Frick MH
    Acta Med Scand Suppl; 1974; 554():33-7. PubMed ID: 4593671
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of beta adrenergic blockade upon exercise-induced changes in blood coagulation and fibrinolysis.
    Britton BJ; Wood WG; Smith M; Hawkey C; Irving MH
    Thromb Haemost; 1976 Apr; 35(2):396-402. PubMed ID: 9703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic properties of beta-adrenergic receptor blocking drugs in man.
    Gibson DG
    Drugs; 1974; 7(1):8-38. PubMed ID: 4151693
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of two formulations of a beta blocker on fibrinolytic response to maximum exercise.
    el-Sayed MS; Davies B
    Med Sci Sports Exerc; 1989 Aug; 21(4):369-73. PubMed ID: 2571061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effect of alprenolol as antihypertensive agent.
    Bengtsson C
    Acta Med Scand Suppl; 1974; 554():9-14. PubMed ID: 4593676
    [No Abstract]   [Full Text] [Related]  

  • 13. Influence of alprenolol on hemodynamic and metabolic responses to prolonged exercise in subjects with hypertension.
    Frisk-Holmberg M; Jorfeldt L; Juhlin-Dannfeldt A
    Clin Pharmacol Ther; 1977 Jun; 21(6):675-84. PubMed ID: 324693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrinolytic and hemostatic changes during and after maximal exercise in males.
    Davis GL; Abildgaard CF; Bernauer EM; Britton M
    J Appl Physiol; 1976 Mar; 40(3):287-92. PubMed ID: 931838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increases in factor VIII complex and fibrinolytic activity are dependent on exercise intensity.
    Andrew M; Carter C; O'Brodovich H; Heigenhauser G
    J Appl Physiol (1985); 1986 Jun; 60(6):1917-22. PubMed ID: 3087936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of 4-hydroxy-alprenolol to adrenergic beta receptor blockade of alprenolol.
    Collste P; Borg KO; Aström H; von Bahr C
    Clin Pharmacol Ther; 1979 Apr; 25(4):416-22. PubMed ID: 34497
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of propranolol on several physiological responses during orthostatic and exercise stress in healthy male subjects.
    Maksud MG; Tristani FE; Coutts KD; Barboriak JJ; Hamilton LH
    Can J Physiol Pharmacol; 1971 Oct; 49(10):867-72. PubMed ID: 4400448
    [No Abstract]   [Full Text] [Related]  

  • 18. The influence of beta-adrenergic blockade upon baseline blood coagulation and fibrinolytic activity and upon the responses to venous occlusion.
    Butler MJ; Smith M; Irving MH; Gordon YB; Ratky SM; Rivers JW; Hawkey C
    Thromb Diath Haemorrh; 1975 Sep; 34(1):169-80. PubMed ID: 1188710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of cardiodepressant potency of nadolol, alprenolol, propranolol and pindolol, beta-blocking agents, in heart-lung preparation and blood-perfused excised papillary muscle preparation of the dog.
    Ono H; Kanazawa Y; O'Hara N; Hashimoto K
    Jpn J Pharmacol; 1984 Dec; 36(4):507-17. PubMed ID: 6151997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of alprenolol on central hemodynamics and exercise tolerance in patients with angina pectoris.
    Jonsson B; Olsson AG; Orö L
    Cardiology; 1973; 58(3):152-61. PubMed ID: 4149331
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.